The Underlying Condition: Increasing Diversity in Clinical Trials

Decrease Font Size Increase Font Size Text Size Print This Page

National Journal: February 20, 2014

CastellaniJohn J. Castellani is president and CEO of the Pharmaceutical Research and Manufacturers of America, which represents the country’s leading biopharmaceutical research and biotechnology companies. (Courtesy photo)

Opinion: African-Americans, at 12 percent of the population, comprise only 5 percent of clinical-trial participants; the numbers for Hispanics are 16 percent and 1 percent. It’s time for that inequity to change, PhRMA’s CEO says.

When a patient picks up her prescription for rheumatoid arthritis, she knows it will enable her to hold her grandson with less pain. The heart-disease survivor takes his statin to avoid bypass surgery that could significantly impact his quality of life. Medical innovations have the power to change lives, as these examples demonstrate. Read More

Share the Clinical Trial Engagement Network


National Minority Quality Forum
1201 15th Street, NW
Suite 340
Washington, DC 20005


Tel: 202.223.7560
Fax: 202.223.7567

Terms of Use     l    Privacy Policy